Neurocrine Biosciences awards 2,567 RSUs to director

MORROW GEORGE J reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

MORROW GEORGE J reported acquisition or exercise transactions in this Form 4 filing.

NEUROCRINE BIOSCIENCES INC director George J. Morrow received a grant of 2,567 Restricted Stock Units as equity compensation. Each RSU represents the right to receive one share of the company’s common stock upon vesting. The RSUs will vest in full on May 27, 2027, and the filing shows 2,567 derivative shares held directly after this award.

Insider Trade Summary

Grant/Award: 2,567 shares

Grant/Award 1 txn

Insider MORROW GEORGE J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restriced Stock Unit	2,567	$0.00	$0.00

Holdings After Transaction: Restriced Stock Unit — 2,567 contracts (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
2. F2. The RSUs will vest in full on May 27, 2027.

Key Figures

RSUs granted: 2,567 units RSU vesting date: May 27, 2027 Shares per RSU: 1 share per RSU +2 more

5 metrics

RSUs granted 2,567 units Restricted Stock Unit grant to director on May 27, 2026

RSU vesting date May 27, 2027 RSUs vest in full on this date

Shares per RSU 1 share per RSU Each RSU delivers one NBIX common share upon vesting

Price per RSU $0.00 Grant/award acquisition, no cash exercise price

Total derivative shares after grant 2,567 shares Total shares underlying RSUs following the transaction

Key Terms

Restricted Stock Unit, RSU, vesting, grant/award acquisition

4 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting."

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

vesting financial

"The RSUs will vest in full on May 27, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NBIX director George J. Morrow report in this Form 4 filing?

George J. Morrow reported receiving a grant of 2,567 Restricted Stock Units. These RSUs are a form of equity compensation and give him the right to receive the same number of Neurocrine Biosciences common shares when they vest.

How many Neurocrine Biosciences (NBIX) RSUs were granted in this insider filing?

The filing shows a grant of 2,567 Restricted Stock Units. Each RSU corresponds to one share of Neurocrine Biosciences common stock, so the award represents potential ownership of 2,567 shares upon vesting.

When do the granted NBIX Restricted Stock Units vest for George J. Morrow?

The RSUs will vest in full on May 27, 2027. Once vesting occurs, each Restricted Stock Unit will convert into one share of Neurocrine Biosciences common stock, assuming all standard conditions for vesting are satisfied.

Is this NBIX Form 4 transaction a stock purchase or a compensation award?

This transaction is a compensation-related award, not an open-market stock purchase. The Form 4 describes a grant of Restricted Stock Units with no cash price per unit, reflecting equity compensation rather than a buy or sell trade.

How many NBIX derivative shares does George J. Morrow hold after this RSU grant?

After the transaction, the filing reports total derivative holdings of 2,567 shares tied to this RSU award. These represent the underlying Neurocrine Biosciences common stock that may be issued when the RSUs vest in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 06:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MORROW GEORGE J

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restriced Stock Unit(1)	$0	05/27/2026		A		2,567		(2)	(2)	Common Stock	2,567	$0	2,567	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

2. The RSUs will vest in full on May 27, 2027.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)